Johnson & Johnson Nanobiotix S.A. Call Options Transaction History
Johnson & Johnson
- $314 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBTX
# of Institutions
13Shares Held
6.43MCall Options Held
0Put Options Held
0-
Perceptive Advisors LLC New York, NY555KShares$2.17 Million0.08% of portfolio
-
Black Rock Inc. New York, NY239KShares$934,5210.0% of portfolio
-
Citigroup Inc3.42KShares$13,3830.0% of portfolio
-
Ubs Group Ag3.1KShares$12,1210.0% of portfolio
-
Gamma Investing LLC Foster City, CA2.86KShares$11,1700.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $136M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...